Want to see SE:S2M full AI Analyst Report?
Top Page
S2Medical AB Class B
(S2M)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by weak and unstable financial performance (sharp 2025 profitability deterioration after a strong 2024) and limited confidence in cash-flow durability. Valuation is also constrained by a negative P/E tied to losses, while technical signals are unavailable and therefore do not provide supportive evidence.
Positive Factors
Debt-free balance sheet
A near-zero debt load materially reduces financial risk and interest burdens, providing durable flexibility to absorb operating swings, fund targeted R&D or working capital, and prioritize strategic initiatives without short-term refinancing pressure.
Negative Factors
High earnings volatility
Marked swings between profit and deep losses weaken predictability of cash flows and capital planning. For a small medical-instruments firm, this volatility makes budgeting, supplier commitments, and longer-term investments riskier over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A near-zero debt load materially reduces financial risk and interest burdens, providing durable flexibility to absorb operating swings, fund targeted R&D or working capital, and prioritize strategic initiatives without short-term refinancing pressure.
Read all positive factors
S2Medical AB Class B (S2M) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr5.62M
Dividend YieldN/A
Average Volume (3M)2.90M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding898,657,040
10 Day Avg. Volume1,954,268
30 Day Avg. Volume2,901,877
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.64
P/FCF Ratio-6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr60.00M
S2Medical AB Class B Business Overview & Revenue Model
Company Description
S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical...
How the Company Makes Money
null...
S2Medical AB Class B Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
63
Positive
Cash Flow
35
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.36M | 14.91M | 6.97M | 4.67M | 7.70M |
| Gross Profit | -2.07M | 14.14M | 5.04M | 5.17M | 7.10M |
| EBITDA | -1.41M | 6.82M | -13.53M | -26.37M | -18.73M |
| Net Income | -10.09M | 5.77M | -22.71M | -29.46M | -20.08M |
Balance Sheet | |||||
| Total Assets | 16.90M | 18.09M | 21.41M | 25.29M | 29.68M |
| Cash, Cash Equivalents and Short-Term Investments | 907.00K | 1.00M | 1.52M | 3.72M | 9.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 207.69K |
| Total Liabilities | 7.03M | 6.29M | 19.75M | 18.22M | 15.00M |
| Stockholders Equity | 9.88M | 11.80M | 1.66M | 7.07M | 14.68M |
Cash Flow | |||||
| Free Cash Flow | -1.35M | 2.49M | -17.67M | -30.03M | -22.76M |
| Operating Cash Flow | 675.00K | 3.12M | -16.52M | -28.13M | -19.67M |
| Investing Cash Flow | -2.02M | -634.00K | -1.15M | -1.76M | -3.02M |
| Financing Cash Flow | 1.25M | -5.54M | 15.47M | 24.14M | 6.85M |
S2Medical AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr134.48M | -2.49 | -80.87% | ― | 7.80% | 42.81% | |
46 Neutral | kr42.97M | -3.61 | -22.31% | 90.91% | ― | ― | |
44 Neutral | kr65.05M | -0.21 | -52.01% | ― | ― | -85.75% | |
41 Neutral | kr5.62M | -0.52 | -69.64% | ― | ― | ― |
* Healthcare Sector Average
SE:S2M
S2Medical AB Class B
0.01
>-0.01
-16.67%
SE:SPEC
SpectraCure AB
0.04
-0.08
-67.23%
SE:NXTCL
NextCell Pharma AB
1.07
-0.14
-11.55%
SE:LARK
CombiGene AB
2.24
-0.12
-5.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.